{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:56:22Z","timestamp":1785599782134,"version":"3.56.0"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Respiratory syncytial virus (RSV) infection is the leading cause of infant hospitalizations and mortality. Lumicitabine, an oral nucleoside analog was studied for the treatment of RSV. The phase 1b and phase 2b studies reported here assessed the safety, pharmacokinetics, and pharmacodynamics of lumicitabine in infants\/neonates hospitalized with RSV. In the phase 1b study, infants (\u22651 to \u226412 months) and neonates (&lt;28 days) received a single-ascending or multiple-ascending doses (single loading dose [LD] then 9 maintenance doses [MD] of lumicitabine, or placebo [3:1]). In the phase 2b study, infants\/children (28 days to \u226436 months old) received lumicitabine 40\/20 mg\/kg, 60\/40 mg\/kg LD\/MD twice-daily or placebo (1:1:1) for 5 days. Safety, pharmacokinetics, and efficacy parameters were assessed over 28 days. Lumicitabine was associated with a dose-related increase in the incidence and severity of reversible neutropenia. Plasma levels of ALS-008112, the active nucleoside analog, were dose-proportional with comparable mean exposure levels at the highest doses in both studies. There were no significant differences between the lumicitabine groups and placebo in reducing viral load, time to viral non-detectability, and symptom resolution. No emergent resistance-associated substitutions were observed at the RSV L-gene positions of interest. In summary, lumicitabine was associated with a dose-related increase in the incidence and severity of reversible neutropenia and failed to demonstrate antiviral activity in RSV-infected hospitalized infants. This contrasts with the findings of the previous RSV-A adult challenge study where significant antiviral activity was noted, without incidence of neutropenia.<\/jats:p>\n<jats:p>Trial registration<\/jats:p>\n<jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02202356\" xlink:type=\"simple\">NCT02202356<\/jats:ext-link> (phase 1b); <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03333317\" xlink:type=\"simple\">NCT03333317<\/jats:ext-link> (phase 2b).<\/jats:p>","DOI":"10.1371\/journal.pone.0288271","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T18:45:16Z","timestamp":1689792316000},"page":"e0288271","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results"],"prefix":"10.1371","volume":"18","author":[{"given":"Abbie","family":"Oey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian A.","family":"Symons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushmita","family":"Chanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathia","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulkanya","family":"Chokephaibulkit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rattapon","family":"Uppala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Bernatoniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Furuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dymphy","family":"Huntjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4267-4196","authenticated-orcid":true,"given":"James","family":"Witek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the 503 and RSV2004 Study Groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"pone.0288271.ref001","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/ijms18081717","article-title":"Respiratory syncytial virus: The influence of serotype and genotype variability on clinical course of infection","volume":"18","author":"S Vandini","year":"2017","journal-title":"Int J Mol Sci"},{"key":"pone.0288271.ref002","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study","volume":"390","author":"T Shi","year":"2017","journal-title":"Lancet"},{"key":"pone.0288271.ref003","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1542\/pir.35.12.519","article-title":"Respiratory syncytial virus infection and bronchiolitis","volume":"35","author":"G Piedimonte","year":"2014","journal-title":"Pediatr Rev"},{"key":"pone.0288271.ref004","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"CB Hall","year":"2009","journal-title":"N Engl J Med"},{"key":"pone.0288271.ref005","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1080\/21645515.2017.1337614","article-title":"Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection","volume":"13","author":"B. Resch","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"pone.0288271.ref006","article-title":"Bronchodilators for bronchiolitis","volume":"2014","author":"AM Gadomski","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0288271.ref007","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.7665.1","article-title":"Current landscape of antiviral drug discovery","volume":"5","author":"W Blair","year":"2016","journal-title":"F1000Res"},{"key":"pone.0288271.ref008","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00003495-200969020-00002","article-title":"Antimicrobial strategies: Inhibition of viral polymerases by 3\u2019-hydroxyl nucleosides","volume":"69","author":"J. Deval","year":"2009","journal-title":"Drugs"},{"issue":"6","key":"pone.0288271.ref009","doi-asserted-by":"crossref","first-page":"e1004995","DOI":"10.1371\/journal.ppat.1004995","article-title":"Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2\u2019-fluoro-4\u2019-chloromethyl-cytidine triphosphate","volume":"11","author":"J Deval","year":"2015","journal-title":"PLoS Pathog"},{"key":"pone.0288271.ref010","doi-asserted-by":"crossref","first-page":"e0154097","DOI":"10.1371\/journal.pone.0154097","article-title":"Biochemical effect of resistance mutations against synergistic inhibitors of RSV RNA polymerase","volume":"11","author":"J Deval","year":"2016","journal-title":"PLoS One"},{"key":"pone.0288271.ref011","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral ALS-008176 in a respiratory syncytial virus challenge study","volume":"373","author":"JP DeVincenzo","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0288271.ref012","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jac\/dky415","article-title":"Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans","volume":"74","author":"K Patel","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"pone.0288271.ref013","article-title":"The anti-respiratory syncytial virus (RSV) nucleoside analog, AL-8112, and its orally bioavailable prodrug, AL-8176, exhibit a high barrier to the emergence of viral resistance","author":"J Hong","year":"2015","journal-title":"Open Forum Infectious Diseases; Oxford University Press"},{"key":"pone.0288271.ref014","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/jm5017279","article-title":"Discovery of 4\u2019-chloromethyl-2\u2019-deoxy-3\u2019,5\u2019-di-O-isobutyryl-2\u2019-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection","volume":"58","author":"G Wang","year":"2015","journal-title":"J Med Chem"},{"key":"pone.0288271.ref015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S2213-2600(20)30320-9","article-title":"Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"S Cunningham","year":"2021","journal-title":"Lancet Respir Med"},{"key":"pone.0288271.ref016","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","article-title":"Antiviral drug resistance: mechanisms and clinical implications","volume":"24","author":"L Strasfeld","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"pone.0288271.ref017","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s10096-017-2998-4","article-title":"Impact of severe hematological abnormalities in the outcome of hospitalized patients with influenza virus infection","volume":"36","author":"A Lalueza","year":"2017","journal-title":"Eur J Clin Micobiol Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0288271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T18:45:59Z","timestamp":1689792359000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0288271"}},"subtitle":[],"editor":[{"given":"Satyajit","family":"Mohapatra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0288271","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]}}}